Side-by-side · Research reference
AOD-9604vsARA 290
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED10/47 cited
BPhase 2HUMAN-REVIEWED17/59 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
SQ · Abdomen · Daily fasted
01Mechanism of Action
Parameter
AOD-9604
ARA 290
Primary target
β3-adrenergic receptor (proposed)Ng 2000
Innate repair receptor (EPO receptor / CD131 heterodimer)
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Feedback intact?
No GH-axis or IGF-1 feedback
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Antibody development
—
Not reported in clinical trials
02Dosage Protocols
Parameter
AOD-9604
ARA 290
Frequency
Once daily, fasted
Once daily
Self-administered subcutaneously.
Lower / starter dose
150 mcg / day
—
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2000
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Duration
8–12 weeks per cycle
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
—
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
Any time of day
No circadian dependence reported.
Half-life
~30 min plasma
—
Standard dose (Phase 2)
—
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
03Metabolic / Fat Loss Evidence
Parameter
AOD-9604
ARA 290
Primary effect
—
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
HbA1c
—
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
Fasting glucose
—
Improved in ARA 290 group
Body composition
—
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
04Side Effects & Safety
Parameter
AOD-9604
ARA 290
Injection site reaction
Mild erythema
Mild, transient
GI symptoms
Rare mild nausea
—
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
No thrombotic events or hypertension reported
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
—
Pregnancy / OB
Avoid
—
Hematopoiesis
—
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
Immunogenicity
—
No antibody formation reported
Absolute Contraindications
AOD-9604
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease (caution with β-receptor agonists)
ARA 290
- ·Hypersensitivity to ARA 290
Relative Contraindications
AOD-9604
- ·Concurrent β-blocker therapy (theoretical antagonism)
- ·Pheochromocytoma
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
05Administration Protocol
Parameter
AOD-9604
ARA 290
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
5. Needle
29–31G, 4–8 mm insulin syringe.
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
06Stack Synergy
AOD-9604
+ MOTS-c
ModerateAOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.
- AOD-9604
- 250–300 mcg SQ · morning fasted (daily)
- MOTS-c
- 5 mg SQ · 2–3× per week (pre-workout)
- Primary benefit
- Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing